Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

2024-08-26 pharmacology and therapeutics Title + abstract only

Show abstract

Acyclovir is a primary treatment for central nervous system (CNS) infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV). However, patient outcomes remain suboptimal with high mortality and morbidity, following current dosing guidelines. Given the lack of alternative therapies, there is a pressing need to optimize acyclovir dosing, especially since initial regimens were developed in the 1980s with incomplete pharmacokinetic data in the CNS. This study aimed to evaluate ...

Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

Predicted journal destinations